Circulating Serum Level of Visfatin in Patients with Endometrial Cancer

Table 3

Visfatin concentration in serum depending on risk factors for endometrial cancer.

	Mean	Median	Min.	Max.	SD
PM/M	14.9/17.1	15.3/18.4	7.1/8.4	20.9/23.3	1.08/1.28	NS
BMI < 25; BMI 25–30	9.2/14.3	10.1/16	6.8/5.9	18.2/31.2	2.01/3.3	0.02
BMI 25–30; BMI > 30	14.3/21.1	16/23.4	5.9/7.8	31.2/36.7	3.3/3.6	0.001
WC < 100/WC > 100	12.2/19.4	14.2/20.6	7.1/11.1	19.5/34.2	1.8/2.7	0.003
Glucose < 110/glucose 110–126	13.6/19.2	15.1/21.8	11.4/13.9	20.02/27.9	1.03/1.6	0.04
Glucose 110–126/glucose > 126	19.2/28.7	21.8/31.2	13.9/17.8	27.9/36.1	1.6/2.4	0.01
DM-metformin/DM-insulin	21.3/28.4	22.3/30.4	16.2/18.7	25.6/35.3	2.6/3.4	0.03
Mean systolic HA < 140 mmHg/mean systolic HA > 140 mmHg	18.2/23.4	19.7/24.5	15.1/16.2	22.2/28.4	1.9/2.3	NS

PM: premenopausal; M: postmenopausal; BMI: body mass index; WC: waist circumference; DM-metformin: diabetes mellitus treated with metformin; DM-insulin: diabetes mellitus treated with insulin; HA: arterial hypertension.